NASDAQ · Biotechnology · USD
Elicio Therapeutics, Inc. (ELTX) Stock Analysis
Elicio Therapeutics, Inc. (ELTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ELTX Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.57
- Previous Close
- $1.57
- Day's Range
- 1.57–1.68
- 52-Week Range
- 1.44–16.00
- Volume
- 269.58K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.98
Valuation
- Market Cap
- $45.24M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −2.16
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$39.57M
- Shares Outstanding
- 27.09M
- 1-Year Return
- −82.37%
Dividend and dates
- Avg Volume
- 306.23K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ELTX closed at $1.67, −82.37% over 1 year.
Elicio Therapeutics, Inc. (ELTX) has a market capitalization of $45.24M.
In fiscal 2025, ELTX reported revenue of $0.00.
ELTX Stock Return by Calendar Year
Elicio Therapeutics, Inc. (ELTX) return since Feb 2021: what $10,000 became
- 1 year
- $10,000 $1,763
- −82.37%
- 5 years
- $10,000 $192
- −98.08%
- Since Feb 2021
- $10,000 $98
- −99.02%
If you had invested $10,000 in Elicio Therapeutics, Inc. (ELTX) at the close on February 5, 2021, the earliest close on record here, it would have been worth $98 at the close on October 21, 2026: −99.02% in total, −55.53% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −79.02% |
| 2025 | +56.08% |
| 2024 | −38.85% |
| 2023 | +2.71% |
| 2022 | −72.00% |
| 2021 (partial year) | −82.96% |
As of October 21, 2026.
ELTX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$39.57M | — |
| 2024 | $0.00 | −$51.90M | — |
| 2023 | $0.00 | −$35.20M | — |
| 2022 | $0.00 | −$28.21M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$37.30M | −$39.57M | — |
| 2024 | $0.00 | — | −$44.99M | −$51.90M | — |
| 2023 | $0.00 | — | −$35.75M | −$35.20M | — |
| 2022 | $0.00 | — | −$23.73M | −$28.21M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
YahooB. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8
BenzingaElicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
YahooHC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target
BenzingaElicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
YahooElicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B